zilganersen sodium · Ionis Pharms Inc · NDA 220210
Zanvastro
Earliest generic entry, as listed
20 May 2041
Blocked by patent: US 11786546.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11786546 | drug substance, drug product, use U-4601 · sets the listed date | 20 May 2041 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220210 · 001 · RLD | solution, intrathecal | EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) | 20 May 2041 |